African American patients with gout: efficacy and safety of febuxostat vs allopurinol by Wells, Alvin F et al.
RESEARCH ARTICLE Open Access
African American patients with gout: efficacy and
safety of febuxostat vs allopurinol
Alvin F Wells
1*, Patricia A MacDonald
2, Solomon Chefo
2 and Robert L Jackson
2
Abstract
Background: African Americans are twice as likely as Caucasians to develop gout, but they are less likely to be
treated with urate-lowering therapy (ULT). Furthermore, African Americans typically present with more
comorbidities associated with gout, such as hypertension, obesity, and renal impairment. We determined the
efficacy and safety of ULT with febuxostat or allopurinol in African American subjects with gout and associated
comorbidities and in comparison to Caucasian gout subjects.
Methods: This is a secondary analysis of the 6-month Phase 3 CONFIRMS trial. Eligible gouty subjects with baseline
serum urate (sUA) ≥ 8.0 mg/dL were randomized 1:1:1 to receive febuxostat 40 mg, febuxostat 80 mg, or
allopurinol (300 mg or 200 mg depending on renal function) daily. All subjects received gout flare prophylaxis.
Primary efficacy endpoint was the proportion of subjects in each treatment group with sUA < 6.0 mg/dL at the
final visit. Additional endpoints included the proportion of subjects with mild or with moderate renal impairment
who achieved a target sUA < 6.0 mg/dL at final visit. Adverse events (AEs) were recorded throughout the study.
Results: Of the 2,269 subjects enrolled, 10.0% were African American and 82.1% were Caucasian. African American
subjects were mostly male (89.5%), obese (BMI ≥ 30 kg/m
2; 67.1%), with mean baseline sUA of 9.8 mg/dL and
mean duration of gout of 10.4 years. The proportions of African American subjects with a baseline history of
diabetes, renal impairment, or cardiovascular disease were significantly higher compared to Caucasians (p < 0.001).
ULT with febuxostat 80 mg was superior to both febuxostat 40 mg (p < 0.001) and allopurinol (p = 0.004).
Febuxostat 40 mg was comparable in efficacy to allopurinol. Significantly more African American subjects with mild
or moderate renal impairment achieved sUA < 6.0 mg/dL in the febuxostat 80 group than in either the febuxostat
40 mg or allopurinol group (p < 0.05). Efficacy rates in all treatment groups regardless of renal function were
comparable between African American and Caucasian subjects, as were AE rates.
Conclusions: In African American subjects with significant comorbidities, febuxostat 80 mg is significantly more
efficacious than either febuxostat 40 mg or allopurinol 200/300 mg. Febuxostat was well tolerated in this African
American population.
Please see related article: http://www.biomedcentral.com/1741-7015/10/15
Background
The rate of gout in the United States has been on the
rise and increases with age, in both men and women
[1-3]. African Americans make up roughly 13% of the
US population [4], and are twice as likely as Caucasians
to develop gout [5,6]. In a prospective cohort study, 571
Caucasian and 352 African American young men were
followed for a median duration of 29 years [5]. The
cumulative incidence of gout in these 2 cohorts was
5.8% and 10.9%, respectively. Yet, African Americans
represent only 10% of the patients treated for gout [7].
Moreover, when they are treated, they are less likely to
receive urate-lowering therapy (ULT) [7]. Furthermore,
African Americans typically present with higher rates of
comorbidities, such as hypertension, obesity, and renal
impairment [8], and have higher rates of diuretic use
compared to Caucasians [9], all of which have been
independently associated with hyperuricemia and gout
[10].
* Correspondence: a.f.wells@att.net
1Rheumatology and Immunotherapy Center, 4225 W. Oakwood Park Court;
Franklin, WI 53132, USA
Full list of author information is available at the end of the article
Wells et al. BMC Musculoskeletal Disorders 2012, 13:15
http://www.biomedcentral.com/1471-2474/13/15
© 2012 Wells et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Gout is characterized by hyperuricemia (serum urate
concentration [sUA] exceeding 6.8 mg/dL, the limit of
urate solubility) and acute and chronic consequences of
monosodium urate crystal deposition, such as tophi and
gout flares [11]. Long-term management of chronic gout
with ULT focuses on achieving and maintaining sUA in
a sub-saturating range (< 6.0 mg/dL) with the goal of
dissolving monosodium urate crystals and decreasing
t h eb o d yp o o lo fu r i ca c i d[ 1 2 , 1 3 ] .U L Tf o ru pt o5
years leads to the elimination of acute flares and reduc-
tion in the size and number of tophi present [14,15].
Available ULT options in the US include xanthine oxi-
dase (XO) inhibitors allopurinol and febuxostat, and
probenecid, a uricosuric. Allopurinol, which is the main-
stay of chronic gout management [16], requires dose
adjustments in gout patients with renal impairment [17],
which may lead to reduced efficacy [18]. Febuxostat is a
selective, non-purine analog XO inhibitor [19] for the
treatment of chronic hyperuricemia in patients with
gout [20]. Data from 3 comparative, blinded, rando-
mized controlled trials (RCTs) have demonstrated the
superior efficacy of febuxostat 80 mg daily compared
with both the commonly prescribed dose of allopurinol
(300 mg) [17] and placebo [21-23]. In addition, both
approved doses of febuxostat, 80 mg and 40 mg, are sig-
nificantly more efficacious than allopurinol (p < 0.001
and p = 0.012, respectively) in achieving the therapeutic
target sUA in subjects with mild-to-moderate renal
impairment [23].
There are no data from prospective RCTs specifically
exploring ULT efficacy and safety in African Americans
with gout. The objective of this post hoc subanalysis of
the CONFIRMS trial [23], the largest ULT RCT to date,
was to examine the urate-lowering efficacy and safety of
febuxostat and allopurinol in hyperuricemic African
American subjects with gout in comparison to Cauca-
sian subjects.
Methods
The 6-month CONFIRMS (NCT# 00430248) trial
enrolled male and female subjects 18 to 85 years of age
with a diagnosis of gout (defined by American Rheuma-
tology Association preliminary criteria [24]) and hyper-
uricemia (sUA ≥ 8.0 mg/dL). Approval was obtained
from Quorum Review Institutional Review Board, Seat-
tle, WA. Subjects provided written, informed consent
and Health Insurance Portability and Accountability Act
authorization prior to any study-related procedure. This
study was conducted with respect for the individual par-
ticipating subjects according to the Declaration of Hel-
sinki, the ICH Harmonised Tripartite Guideline for
GCP, and all applicable local regulations. Exclusion cri-
teria included secondary hyperuricemia, xanthinuria,
severe renal impairment (estimated creatinine clearance
[eCLcr] < 30 mL/min, calculated by Cockcroft-Gault
formula corrected for ideal body weight [25,26]), alanine
aminotransferase and aspartate aminotransferase values
> 1.5 times the upper limit of normal, consumption of >
14 alcoholic drinks per week or a history of alcoholism
or drug abuse within 5 years, or medical condition that
would interfere with treatment, safety, or adherence to
the study protocol. In addition, subjects with known
hypersensitivity to febuxostat, allopurinol, naproxen, any
other non-steroidal anti-inflammatory agents, aspirin,
lansoprazole, colchicine, or any components of these
drugs formulations were excluded.
Subjects were randomized 1:1:1 to receive a daily dose
of either febuxostat 40 mg, febuxostat 80 mg (Uloric
®;
Takeda Global Research & Development Center, Inc;
Deerfield, IL), or allopurinol (Apotex; Weston, FL,
USA). Subjects randomized to allopurinol were to
receive 300 mg daily if baseline renal function was nor-
mal (eCLcr ≥ 90 mL/min) or mildly impaired (eCLcr 60
to < 90 mL/min); subjects with moderate renal impair-
ment (eCLcr 30 to < 60 mL/min) were to receive 200
mg daily.
Throughout the 6-month treatment period, subjects
received prophylaxis for gout flares, self-administering
either colchicine (Westward Pharmaceutical Corpora-
tion; Eatontown, NJ) 0.6 mg daily, or naproxen (West-
ward Pharmaceutical Corporation) 250 mg twice daily.
Subjects with eCLcr < 50 mL/min were not to receive
naproxen. All subjects receiving naproxen prophylaxis
also received lansoprazole 15 mg daily (Takeda Global
Research & Development Center, Inc).
The primary efficacy endpoint of CONFIRMS was the
proportion of subjects in each treatment group who
achieved a target sUA < 6.0 mg/dL at final visit [23]. In
the primary CONFIRMS analysis of the total cohort (N
= 2,269), non-inferiority of febuxostat 40 mg compared
to allopurinol 300/200 mg dose was demonstrated.
Binomial 95% confidence intervals (CIs) were calculated
for the difference between the 2 groups in achieving the
primary efficacy endpoint. Non-inferiority was declared
if the lower limit of the 95% CI for difference in the
proportion of subjects achieving an sUA < 6.0 mg/dL at
the last visit was greater than -10%. The difference
between the febuxostat 40 mg group (45.2%) and the
allopurinol group (42.1%) was 3.1% (95% CI: -1.9% -
8.1%), thus demonstrating non-inferiority [23]. Efficacy
comparisons between treatment groups were made
using Fisher’s exact test (two-tailed, 0.05 significance
level. Additional efficacy endpoints were the proportion
of subjects in each treatment group with mild and with
moderate renal impairment who achieved a target sUA
< 6.0 mg/dL at final visit. Pairwise comparisons were
made between treatment groups with Fisher’s exact test.
The objectives of our current analyses were to assess
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among African American subjects and compare these
results with those observed in the subgroup of Cauca-
sian subjects enrolled in the CONFIRMS trial.
All treatment-emergent adverse events (AEs) were
recorded using Medical Dictionary for Regulatory Activ-
ities (MedDRA). Gout flares were not considered AEs
and were reported separately.
Statistical analyses of the achievement of the efficacy
endpoints for each treatment group have been pre-
viously described in detail [23]. In addition, to determine
statistically significant differences between African
American and Caucasian subjects for baseline character-
istics of age, body mass index (BMI), baseline sUA, and
years with gout, analysis of variance was used; for all
other categorical baseline variables, Fisher’se x a c tt e s t
was used. In addition, Fisher’se x a c tt e s tw a su s e dt o
determine statistical significant differences between the
proportions of African American and Caucasian subjects
within each treatment group who achieved the primary
and additional efficacy endpoints, and differences in
rates of AEs between African American and Caucasian
subjects.
Results
Of the 2,269 subjects who enrolled in the CONFIRMS
trial, 228 (10.0%) were African American and 1,863
(82.1%) were Caucasian. Fifty-two (22.8%) and 329
(17.7%) African Americans and Caucasian subjects,
respectively, discontinued from the study prematurely
(Figure 1). The most common primary reason for pre-
mature discontinuation among African American sub-
jects was lost to follow-up (n = 22; 9.6%), while AEs
were the most frequent primary reason for Caucasians
(n = 149; 8.0%). Compliance with therapy (≥ 90% com-
pliant), calculated as the number of capsules taken
divided by the number of days on drug, was lower
among African Americans compared to Caucasians;
72.4% vs 82.1%, respectively. When analyzed by treat-
ment group, compliance (≥ 90%) for African American
subjects in the febuxostat 40 mg, febuxostat 80 mg, and
allopurinol treatment groups was 66.3%, 76.9%, and
74.6%, respectively, while it was 82.4%, 82.2%, and
81.6%, respectively, for Caucasian subjects.
At baseline, compared to the Caucasian subgroup, the
African American subgroup had significantly more
women (10.5% vs 5.1%; p < 0.001), higher mean BMI
(34.0 kg/m
2 vs 32.8 kg/m
2; p = 0.006), higher mean sUA
(9.8 mg/dL vs 9.5 mg/dL; p < 0.001), and lower mean
duration of gout (10.4 years vs 11.8 years; p = 0.030). In
addition, the proportions of subjects with a history of
diabetes, renal impairment, or cardiovascular disease at
baseline were significantly higher among African Ameri-
cans compared to Caucasians (p < 0.001; Table 1).
The primary efficacy endpoint of this analysis, sUA <
6.0 mg/dL at final visit, was achieved by 34.9%, 66.7%,
and 41.8% of African American subjects in the febuxostat
40 mg, febuxostat 80 mg, and allopurinol 200/300 mg
groups, respectively. Febuxostat 80 mg was significantly
more efficacious than both febuxostat 40 mg (p < 0.001)
and allopurinol 200/300 mg (p = 0.004). Similarly, among
Caucasian subjects, significantly higher proportions of
subjects in the febuxostat 80 mg group (68.4%) achieved
sUA < 6.0 mg/dL compared to those in the febuxostat 40
mg group (46.8%; p < 0.001) and in the allopurinol 200/
300 mg group (43.3%; p < 0.001). No statistical difference
was observed in the urate-lowering efficacy rate between
febuxostat 40 mg and allopurinol 200/300 mg in either
the African American or Caucasian subgroup. Figure 2A
provides comparisons of the achievement of the primary
endpoint between African American and Caucasian sub-
jects within each treatment group. Achievement of the
primary efficacy endpoint was comparable between Afri-
can American and Caucasian subjects when compared
within treatment groups for either febuxostat 80 mg or
allopurinol 200/300 mg. Although febuxostat was effec-
tive in African Americans, significantly less African
American subjects achieved sUA < 6.0 mg/dL with
febuxostat 40 mg than did Caucasian subjects (p = 0.046).
In both African American and Caucasian subjects with
mild renal impairment, the urate-lowering efficacy of
febuxostat 80 mg was greater than that of either febuxostat
40 mg (p = 0.002 in African Americans; p <0 . 0 0 1i nC a u c a -
sians) or allopurinol 200/300 mg (p =0 . 0 1 6i nA f r i c a n
Americans; p < 0.001 in Caucasians). The same pattern was
also observed in subjects with moderate renal impairment.
Figures 2B/C provide comparisons in efficacy between Afri-
can American and Caucasian subjects with mild or moder-
ate renal impairment within each treatment group; efficacy
rates between African American and Caucasian subjects
within each treatment group were comparable.
In the febuxostat 40 mg, febuxostat 80 mg, and allo-
purinol 200/300 mg groups, 30%, 31%, and 30% of Afri-
can Americans, respectively, and 30%, 31%, and 25% of
Caucasians, respectively, required treatment for acute
gout flares during the 6 months of the study.
Overall rates of AEs were comparable across treatment
groups for both African American and Caucasian subjects.
At least 1 AE was reported in the febuxostat 40 mg, febuxo-
stat 80 mg, and allopurinol 200/300 mg groups by 45.8%,
60.3%, and 44.8% of African American subjects, respec-
tively, and by 57.3%, 53.4%, and 58.7% of Caucasian sub-
jects, respectively. Table 2 lists the most frequently
reported AEs for African American and Caucasian subjects.
Overall, rates of serious AEs were comparable across
treatment groups in African American subjects as well
as in the Caucasian subjects. Among African American
subjects, 3.6%, 3.8%, and 4.5% in the febuxostat 40 mg,
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respectively, reported at least 1 serious AE, while 2.3%,
3.9%, and 4.3% of Caucasian subjects, respectively,
reported at least 1 serious AE. One (1.2%) African
American subject, in the febuxostat 40 mg group,
reported a cardiac serious AE. Among Caucasian sub-
jects, cardiac serious AEs were reported by 3 (0.5%), 5
(0.8%), and 5 (0.8%) subjects in the febuxostat 40 mg,
febuxostat 80 mg, and allopurinol 200/300 mg groups,
respectively. Five subjects died during the CONFIRMS
trial [23]–2 were African American (1 from sudden
death and the other from necrotizing sepsis after surgery
for lung carcinoma) and 3 were Caucasian (1 hyperten-
sive heart disease, 1 anaphylactic shock from fire ant
stings, and 1 brain edema and chronic pulmonary lung
disease). No death was considered by investigators to be
related to study drug.
Discussion
Differences in the efficacy and safety of various drugs in
different racial groups have been well documented and
can be attributed to differing rates of comorbid
conditions, concomitant medication use, and underlying
genetic variations in the enzymes involved in drug meta-
bolism [27]. For example, dosing adjustments for war-
farin are recommended in African American patients
due to decreased metabolism of the drug, which can
lead to increased risk for bleeding. Clinical and genetic
components that may affect warfarin metabolism in
African Americans include age, weight, cerebrovascular
disease, and the presence of certain variants of the hepa-
tic isoenzyme cytochrome P450 (CYP) 2C9, the primary
metabolizer of warfarin [28]. Febuxostat is extensively
metabolized in the liver by conjugation via uridine
diphosphate glucuronosyltransferase (UGT) enzymes,
including UGT1A1, UGT1A3, UGT1A9, and UGT2B7,
and, to a much lesser extent, oxidation via CYP1A2,
2C8, 2C9, and non-P450 enzymes [20]. Different gene
variants for UGT1A1, UGT1A9, and CYP2C9 have been
identified in African Americans vs Caucasians [29-31].
However, based on our results in this limited number of
African American subjects, these genetic variants do not
appear to affect the metabolism of febuxostat in such a
way that would interfere with its efficacy.
Figure 1 Flow of African American and Caucasian Subjects Through the CONFIRMS Trial.
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can population [5,6] have been attributed to high rates
of comorbid conditions associated with increased risk
for gout [10], such as diabetes, hypertension, obesity,
and renal disease [8]. Along with clinical differences that
may contribute to increased risk for developing gout,
identification of underlying genetic differences in the
various enzymes and transporters involved in purine
metabolism and urate renal excretion could shed further
light on why African Americans are affected with gout
at higher rates. For example, a number of renal urate
transporters and their genes have been identified. Var-
iants of these genes influence sUA. While some of these
genetic variants strongly influence sUA in both Cauca-
sians and African Americans, others are more specifi-
cally associated with one race or the other [32-34].
There is a growing body of evidence that both hyper-
uricemia and gout increase the risk for the development
and/or progression of renal dysfunction, cardiovascular
disease, hypertension, metabolic syndrome, and diabetes
[35-40], and all-cause and cardiovascular-related mortal-
ity [41,42]. In addition, the evidence suggests a disparity
between African Americans and Caucasians. In the
Atherosclerosis Risk in Communities Study, a prospec-
tive epidemiological cohort study, increasing sUA as a
continuous variable–a f t e ra d j u s t i n gf o ra g e ,b a s e l i n e
Table 1 Comparison of Baseline Demographics and Characteristics Between African American and Caucasian Subjects
in the CONFIRMS Trial
Variable African American N = 228 Caucasian N = 1,863 p value
a
Gender, n (%)
Male 204 (89.5) 1,768 (94.9) < 0.001
Female 24 (10.5) 95 (5.1)
Age (years)
Mean ± SD 53.2 ± 10.45 53.0 ± 11.80 0.799
Body Mass Index (kg/m
2)
Mean ± SD 34.0 ± 7.47 32.8 ± 6.09 0.006
Alcohol Use, n (%)
Non-/Ex-drinker 88 (38.6) 563 (30.2) 0.010
Drinker (1-14 drinks/week) 140 (61.4) 1,300 (69.8)
Tobacco Use, n (%)
Non-/Ex-tobacco User 177 (77.6) 1,528 (82.0) 0.107
Tobacco User 51 (22.4) 335 (18.0)
Serum Urate (mg/dL)
Mean ± SD 9.8 ± 1.24 9.5 ± 1.16 < 0.001
Years with Gout
Mean ± SD 10.4 ± 8.28 11.8 ± 9.49 0.030
Tophi Present, n (%)
No 169 (74.1) 1,482 (79.5) 0.058
Yes 59 (25.9) 381 (20.5)
Renal Function,
b n (%)
Moderately Impaired 69 (30.3) 299 (16.0) < 0.001
Mildly Impaired 109 (47.8) 884 (47.5)
Normal 50 (21.9) 680 (36.5)
Medical History, n (%)
Any cardiovascular disease 170 (74.6) 1,024 (55.0) < 0.001
Hypertension 165 (72.4) 937 (50.3) < 0.001
Coronary artery disease 25 (11.0) 161 (8.6) 0.245
Cardiac arrhythmia 19 (8.3) 202 (10.8) 0.245
Diabetes 57 (25.0) 229 (12.3) < 0.001
Hypercholesterolemia 19 (8.3) 130 (7.0) 0.454
Hyperlipidemia 83 (36.4) 776 (41.7) 0.128
Use of low-dose aspirin (≤ 325 mg daily) 40 (17.5) 343 (18.4) 0.749
ap values determined from analysis of variance model for age, body mass index, baseline serum urate, and years with gout, and by Fisher’s exact test for all
other variables.
bModerate baseline renal impairment: estimated creatinine clearance (eCLcr) 30 to < 60 mL/min; mild baseline renal impairment: eCLcr 60 to < 90 mL/min;
normal: eCLcr ≥ 90 mL/min.
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ing–was shown to significantlyi n c r e a s et h er i s kf o rt h e
development of hypertension in African Americans, but
not for Caucasians, regardless of concomitant medica-
tion use [43]. In another such study, each unit increase
in sUA was associated with a higher risk for cardiovas-
cular mortality in African American men and women
compared to their Caucasian counterparts [44].
Proper management of the underlying hyperuricemia
of gout is necessary for the proven reduction in the clin-
ical manifestations of the disease, including gout flares
and tophi [14,15,45-47]. Although not approved for
such use, treatment with allopurinol or febuxostat has
also been shown to ameliorate renal damage induced by
hyperuricemia in rats [48,49], and to stabilize or even
improve renal function in humans [50-53]. A recent
study in humans has also demonstrated the cardiovascu-
lar-protective impact of lowering sUA levels [35]. There-
fore, proper management of African American gout
patients goes beyond the acute treatment of flares,
tophi, or kidney stones and incorporates effective reduc-
tion and maintenance of sUA to target levels of < 6.0
mg/dL.
While the clinical benefits of reducing sUA long-term
likely extend beyond relief from gout, providing opti-
mum management to African American gout patients
may be challenging. Data from the National Ambulatory
Medical Care Survey reveal that of 3.9 million outpati-
ent visits with a gout diagnosis that occurred in the US
during 2002, only 10% were made by African Americans
vs 82% by Caucasians [7]. Caucasians with a gout visit
were more likely to have private insurance (46%) com-
pared to African Americans (11%; p < 0.001) and,
importantly, African Americans were less likely than
Caucasians to receive ULT with allopurinol (odds ratio
[OR] 0.18; 95% CI, 0.04-0.78; p = 0.02) [7]. In addition,
African American patients with gout are more likely to
be non-adherent with ULT than Caucasian patients (OR
1.86; 95% CI, 1.52-2.27) [54]. Interestingly, we observed
in this analysis that the African American subjects were
3-times more likely to be lost to follow up than the
Caucasian subjects (9.6% vs 3.0%, respectively) and less
adherent with therapy (72.4% vs 82.1%, respectively).
There are no published studies specifically examining
racial disparities in the diagnosis and management of
gout. Therefore possible explanations for low rates of
gout diagnosis despite higher risk, lower use of ULT,
and lower compliance with therapy among African
Americans compared to Caucasians can only be inferred
from other chronic diseases. In a 2002 report on ethnic
disparities in arthritis and musculoskeletal diseases [55],
Jordan et al. attributed some disparities to ethnic differ-
ences in access to care, care-seeking behavior, and utili-
zation of care. According the 2010 National Healthcare
Disparities Report [56], healthcare quality and access
continue to be suboptimal for minority and low-income
groups. Perceived provider discrimination, which is
higher among minorities, can lead to delay in seeking
health care [57]. There are noted racial differences in
Figure 2 Comparative Efficacy of Urate-Lowering Therapy
Between African American and Caucasian Subjects Within
Treatment Groups: A) All Subjects; B) Subjects With Mild Renal
Impairment (eCLcr 60 to < 90 mL/min); and C) Subjects With
Moderate Renal Impairment (eCLcr 30 to < 60 mL/min).
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American patients attach greater importance to the risks
of toxicity and less importance to the likelihood of bene-
fit than their Caucasian counterparts [58,59]. Similarly,
among patients with at least moderately severe osteoar-
thritis, African Americans were significantly less likely
than Caucasians to perceive the benefit of total joint
arthroplasty and more likely to recognize barriers to the
procedure [60]. Based on just the above small sampling
of the literature, it is likely that the underlying reasons
for racial disparities in gout are multifactorial and
require investigation.
ULT with febuxostat 80 mg was significantly better
than either febuxostat 40 mg or allopurinol 200/300 mg
in the African American cohort of hyperuricemic gout
subjects with high rates of comorbidities. This was also
observed in the Caucasian cohort and reflects the overall
results of the CONFIRMS trial [23]. Similarly, among
both African Americans and Caucasians with mild or
moderate renal impairment, febuxostat 80 mg was sig-
nificantly better at achieving sUA < 6.0 mg/dL com-
pared to either febuxostat 40 mg or allopurinol 200/300
mg.
When the efficacy of each treatment group was com-
pared between African American and Caucasian sub-
jects, the only significant difference observed was in the
febuxostat 40 mg treatment group, with lower efficacy
observed in African American subjects in the overall
cohort (34.9% vs 46.8%; p = 0.046). One plausible expla-
nation for this observed difference may be the noted dif-
ference in compliance with treatment. Within the
febuxostat 40 mg group, Caucasian subjects had a
considerably higher compliance rate (82.4%) than their
African American counterparts (66.3%). This difference
was greater than those observed in the other 2 treat-
ment groups. In addition, a large numerical difference
was observed in subjects with mild renal impairment
(37.8% vs 54.9%) but this did not reach statistical signifi-
cance (p = 0.055). The lack of significant difference is
likely due to the small number of African American
subjects. In addition, no significant differences were
observed between African American and Caucasian sub-
jects with mild or with moderate renal impairment in
the efficacy of febuxostat 80 mg or allopurinol 200/300
mg. In each treatment group the percentages of African
American and Caucasian subjects that required treat-
ment for gout flares were comparable. Flare rates during
initial ULT correlate with the extent of sUA decrease
[61], therefore similar rates reflect comparable efficacy
between the two groups. Along with comparable effi-
cacy, ULT with either dose of febuxostat or allopurinol
200/300 mg was well-tolerated by both African Ameri-
cans and Caucasian subjects.
Limitations of this subanalysis include its post-hoc
nature and the low number of African Americans
enrolled in the CONFIRMS trial compared to Cauca-
sians. Despite the fact that they develop gout at higher
rates than Caucasians [5,6], in the CONFIRMS trial,
along with other ULT RCTs, African Americans com-
prised ≤ 10% of the study population [21-23]. Underre-
presentation of African Americans in the febuxostat
clinical trials is not unique to the enrollment patterns
observed for the majority of Phase 3 clinical intervention
trials conducted in the US and reflects the continued
Table 2 Most Frequently Reported Adverse Events and Elevated Serum Liver Function Tests in African American and
Caucasian Subjects
African American N = 228 Caucasian N = 1863 p value
a
Total subjects reporting ≥ 1 AE, n (%) 115 (50.4) 1052 (56.5) 0.090
Most frequently reported AEs, n (%)
Liver function analyses 8 (3.5) 141 (7.6) 0.020
Upper respiratory tract infections 15 (6.6) 141 (7.6) 0.689
Diarrhea 10 (4.4) 128 (6.9) 0.202
Musculoskeletal and connective tissue signs and symptoms 9 (3.9) 89 (4.8) 0.739
Joint related signs and symptoms 7 (3.1) 69 (3.7) 0.851
Elevated liver function tests, n/N (%)
ALT
≥ 2X ULN 5/206 (2) 172/1737 (10) < 0.001
≥ 3X ULN 1/206 (< 1) 50/1737 (3) 0.037
AST
≥ 2X ULN 8/206 (4) 93/1736 (5) 0.505
≥ 3X ULN 3/206 (1) 24/1736 (1) 0.760
AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal
ap values are from Fisher’s exact test
AEs are reported by MedDRA High Level Term. Most frequent events are those occurring in at least 3 percent of African American subjects.
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populations [62]. However, the data reported here repre-
sents the first report of ULT efficacy and safety in Afri-
can American gout patients. Additional studies
incorporating greater numbers of minorities are needed
to confirm our results.
Conclusions
ULT is equally efficacious in African American and
Caucasian gout patients. For African American gout
patients with mild or moderate renal impairment,
febuxostat 80 mg is significantly more effective at lower-
ing sUA to < 6.0 mg/dL than febuxostat 40 mg or the
commonly prescribed doses of allopurinol (200 or 300
mg) [17].
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